PCLX-001 is under clinical development by Pacylex Pharmaceuticals and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PCLX-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PCLX-001 overview

PCLX-001 (DDD86481) is under development for the treatment of relapsed or refractory acute myeloid leukemia, lung cancer, colon cancer, breast cancer, solid tumors including non-small cell lung cancer, small-cell lung cancer, colorectal cancer, bladder cancer, and B-cell non-Hodgkin lymphomas including diffuse large B-cell lymphoma, high grade B-cell lymphoma, Burkitt lymphoma, mantle cell lymphoma, follicular lymphoma, pancreatic cancer, appendiceal cancer and unspecified indication. The drug candidate administered orally. It acts by targeting N-myristoyl transferase (NMT). It was also under development for the treatment of Aspergillus fungemia.

Pacylex Pharmaceuticals overview

Pacylex Pharmaceuticals (Pacylex) is an oncology therapeutics and diagnostics company that discovers and develops precision medicine solutions to treat multiple common cancers. The company is developing its lead product candidate PCLX-001, an orally bio-available small molecule that helps in N-myristoyl transferase (NMT) inhibition. Pacylex is evaluating drug usage in various therapeutic areas which include Hodgkin lymphomas, non-Hodgkin lymphomas, solid tumors, acute myeloid leukemia, lung and bronchus cancer, hematologic cancer, and breast cancer. The company seeks to collaborate with series B investors for the development of phase 2 programs in diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML). Pacylex is headquartered in Edmonton, Alberta, Canada.

For a complete picture of PCLX-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.